Geology Reports⌕ Search

Geology topics

L.G. Anderson

Publications and source records attributed to L.G. Anderson.

2 recordsLinked to original sources

Processes of multibathyal aragonite undersaturation in the Arctic Ocean

During 3 years of study (2010–2012), the western Arctic Ocean was found to have unique aragonite saturation profiles with up to three distinct aragonite undersaturation zones. This complexity is produced as inflow of Atlantic-derived and Pacific-derived water masses mix with Arctic-derived waters, which are further modified by physiochemical and biological processes. The shallowest aragonite undersaturation zone, from the surface to ∼30 m depth is characterized by relatively low alkalinity and other dissolved ions. Besides local influence of biological processes on aragonite undersaturation of shallow coastal waters, the nature of this zone is consistent with dilution by sea-ice melt and invasion of anthropogenic CO 2 from the atmosphere. A second undersaturated zone at ∼90–220 m depth (salinity ∼31.8–35.4) occurs within the Arctic Halocline and is characterized by elevated p CO 2 and nutrients. The nature of this horizon is consistent with remineralization of organic matter on shallow continental shelves bordering the Canada Basin and the input of the nutrients and CO 2 entrained by currents from the Pacific Inlet. Finally, the deepest aragonite undersaturation zone is at greater than 2000 m depth and is controlled by similar processes as deep aragonite saturation horizons in the Atlantic and Pacific Oceans. The comparatively shallow depth of this deepest aragonite saturation horizon in the Arctic is maintained by relatively low temperatures, and stable chemical composition. Understanding the mechanisms controlling the distribution of these aragonite undersaturation zones, and the time scales over which they operate will be crucial to refine predictive models.

Journal of Geophysical Research: Oceans↗

Determination of pharmaceutical compounds in surface- and ground-water samples by solid-phase extraction and high-performance liquid chromatography-electrospray ionization mass spectrometry

Commonly used prescription and over-the-counter pharmaceuticals are possibly present in surface- and ground-water samples at ambient concentrations less than 1 μg/L. In this report, the performance characteristics of a combined solid-phase extraction isolation and high-performance liquid chromatography–electrospray ionization mass spectrometry (HPLC–ESI-MS) analytical procedure for routine determination of the presence and concentration of human-health pharmaceuticals are described. This method was developed and used in a recent national reconnaissance of pharmaceuticals in USA surface waters. The selection of pharmaceuticals evaluated for this method was based on usage estimates, resulting in a method that contains compounds from diverse chemical classes, which presents challenges and compromises when applied as a single routine analysis. The method performed well for the majority of the 22 pharmaceuticals evaluated, with recoveries greater than 60% for 12 pharmaceuticals. The recoveries of angiotensin-converting enzyme inhibitors, a histamine (H2) receptor antagonist, and antihypoglycemic compound classes were less than 50%, but were retained in the method to provide information describing the potential presence of these compounds in environmental samples and to indicate evidence of possible matrix enhancing effects. Long-term recoveries, evaluated from reagent-water fortifications processed over 2 years, were similar to initial method performance. Method detection limits averaged 0.022 μg/L, sufficient for expected ambient concentrations. Compound-dependent matrix effects on HPLC/ESI-MS analysis, including enhancement and suppression of ionization, were observed as a 20–30% increase in measured concentrations for three compounds and greater than 50% increase for two compounds. Changing internal standard and more frequent ESI source maintenance minimized matrix effects. Application of the method in the national survey demonstrates that several pharmaceuticals are routinely detected at 0.010–0.100 μg/L concentrations.

Journal of Chromatography A↗